Exhibit 99.1

Compelling Results Demonstrating Effectiveness of Possis' AngioJet(R)
                      Treatment Presented at TCT


    MINNEAPOLIS--(BUSINESS WIRE)--Oct. 23, 2006--Possis Medical, Inc.
(NASDAQ:POSS) announced that Dr. Georgios Sianos of the Thoraxcentre
in Rotterdam, the Netherlands, today presented compelling results
showing the clinical value of AngioJet(R) treatment for coronary
arterial thrombus in heart attack patients at the 2006 Transcatheter
Cardiovascular Therapeutics (TCT) conference in Washington, D.C. TCT,
which is taking place October 22-27, is the premier venue for
interventional clinical science. Dr. Sianos' results show that
AngioJet thrombectomy in heart attack patients with large thrombus
prior to treatment with drug eluting stents markedly reduces the
incidence of stent thrombosis in follow-up out to two years.

    "TCT is the pre-eminent event in interventional cardiology and
we're very excited to have Dr. Sianos present his findings in such a
visible and respected forum," said Robert Dutcher, chairman, president
and CEO of Possis Medical. "The favorable results reported by Dr.
Sianos and his colleagues reinforce other research that identifies
thrombus as a significant risk factor for subsequent major
complications such as stent thrombosis. The results also confirm that
for heart attack patients with large thrombus, AngioJet thrombectomy
before treatment with drug eluting stents provides safer long-term
outcomes."

    Said Dutcher, "New reports concerning the higher risk of coronary
blood clots forming after implantation of drug eluting stents present
an important opportunity to establish the value of AngioJet
thrombectomy in reducing stent thrombosis. We're very encouraged by
Dr. Sianos' work at the Thoraxcentre in Rotterdam, and new research
from others in this field."

    The world renowned Thoraxcentre at Erasmus University in
Rotterdam, the Netherlands, is one of Europe's largest interventional
cardiology centers and has extensive experience with drug eluting
stents.

    About Possis Medical, Inc.

    Possis Medical, Inc., develops, manufactures and markets
pioneering medical devices for the large and growing cardiovascular
and vascular treatment markets. The Company's AngioJet System is the
world's leading mechanical thrombectomy system with FDA approval to
remove large and small thrombus from coronary arteries, coronary
bypass grafts, peripheral arteries and A-V grafts and native fistulas.

    Certain statements in this press release constitute
"forward-looking statements" within the meaning of Federal Securities
Laws. Some of these statements relate to AngioJet System product
performance, market acceptance, regulatory approvals, and new product
introductions. These statements are based on our current expectations
and assumptions, and entail various risks and uncertainties that could
cause actual results to differ materially from those expressed in such
forward-looking statements, such as, the effectiveness of our sales
and marketing efforts, our ability to effectively manage new product
development timelines, and our ability to generate suitable clinical
data. A discussion of these and other factors that could impact the
Company's future results are set forth in the cautionary statements
included in the Company's Form 10-K for the year ended July 31, 2006,
filed with the Securities and Exchange Commission.

    CONTACT: Possis Medical, Inc.
             Jules L. Fisher, Vice President, Finance and
             Chief Financial Officer, 763-450-8011
             jules.fisher@possis.com